A new study validates NRG1 gene fusions as a targetable driver of advanced NRG1 fusion-positive cancers, adding support for ...

Julie Patterson, Pharm.D., Ph.D., of the National Pharmaceutical Council, tells Managed Healthcare Executive at the annual ...

None of the cell and gene therapies that reached the final regulatory submission stage were rejected by the FDA.

Eric Cannon, PharmD, FAMCP, discusses how LPA1 receptor activation promotes fibrosis in idiopathic pulmonary fibrosis (IPF) ...

Doing more to incorporate caregiver burden into value assessments and cost-effectiveness research of Duchene muscular dystrophy treatments was the focus of a recent International Society for ...

Juan Carlos Scott, president and CEO of the Pharmaceutical Care Management Association (PCMA), and Marissa Schlaifer, RPh, ...

Co-presenter, Sean Shirk, Pharm.D., director of specialty clinical solutions at Prime Therapeutics, discussed this topic ...

At the AMCP 2025 meeting, Julie Patterson, Pharm.D., Ph.D., explained that the impact of the IRA drug negotiation program on patient access is still unclear, but early research shows that coverage for ...

At the AMCP 2025 annual meeting, Sean Shirk, Pharm.D., stressed the need for payers to stay informed and engaged with legislation to sustain site-of-service efforts despite growing restrictions.

Researchers say payers should take the added costs of drugs prescribed to deal with GLP-1 side effects into account when ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...